A recent retrospective study led by Dr. Marilyn J. Siegel and her team at the Washington University School of Medicine in St. Louis has shed light on a critical issue in cancer care: routine clinical reads are more prone to overdiagnosing progressive disease when compared to RECIST 1.1 interpretations. This discrepancy holds significant implications, potentially leading to the premature discontinuation of effective treatments for cancer clinical trial participants and patients under standard care.
In this study, mint Lesion software was utilized for the criteria-based reads, determining overall response assessments according to RECIST 1.1 criteria, and generating structured reports for the clinical trial's principal investigator.
To learn more about the study's insights into the discrepant assessments and the suggested steps for mitigating this issue, click here.
Study Discovers Overdiagnosis of Progressive Cancer in Routine Clinical Evaluations
Related Resources
Related Resources
Number of Clinical Trials in Oncology has increased strongly during the last 10 years
Cancer cases and cancer related deaths continue to increase globally. While new cancer therapies are being identified offering new options for…
New TNM- and RADS-Classification in mint Lesion
With the aid of various clinical reading templates, mint Lesion provides context-specific support in the application of established radiological…
New mint Lesion 3.4 Software presented at RSNA 2017
With mint Lesion 3.4, reproducible assessment and structured reporting of significant image observations are easier than ever. Numerous improvements…